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Design and Synthesis of Peripherally Selective CB1 Antagonist/CB2 Agonist to Hinder and Reverse 
Hepatic Fibrosis 
 Hepatic fibrosis, a precursor to cirrhosis, has recently increased incidence. The progression of 
fibrosis to cirrhosis is a dominant instigator of hepatic failure and liver cancer, thus making the inhibition 
of this progression a promising treatment option 
1
. 
 There have been two cannabinoid receptros, CB1 and CB2, identified to date.  Modulation of 
these gene protein coupled receptors is know to have psychoactive, inflammatory, and proliferative in 
humans 
2
. These two receptors have beenlinked to liver fibrosis. The CB1 receptors in the liver enhance 
the progression of liver disease by promoting fibrinogenesis 
3
. The CB2 receptors have been reported to  
inhibit or reverse fibrinogenesis 
4
.  
 Therapies that target CB1 receptors in the central nervous system (CNS) have adverse mood-
related side effects. However, peripherally selective CB1 antagonists provide an alternative strategy that 
avoids CNS sode effects. This study aimed to synthesize peripherally selective CB1 antagonist/CB2 
agonist that mitigates hepatic fibrosis and its secondary pathologies.   
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